Company: CYTK
Filing Date: 2025-12-12
Form Type: 8-K
Source: 0001193125-25-316904
Chunk: 0

Company: CYTOKINETICS INC
Filing Date: 2025-12-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On December 12, 2025, Cytokinetics, Incorporated ("Cytokinetics" or the "Company") announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “ Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential approval of MYQORZO® (aficamten) by the European Commission or any other instrumentality or regulatory agency as a treatment for obstructive hypertrophic cardiomyopathy or any other indication. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from the forward-looking statements contained in this Current Report on Form 8-K. Any forward-looking statements that Cytokinetics makes in this Current Report on Form 8-K speak only as of the date of this report. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                             CYTOKINETICS, INCORPORATED               
  Date:      December 12, 2025      By:      /s/ John O. Faurescu                     
                                             John O. Faurescu